Explore

Trendline Trendline
Novo Nordisk CEO Transition: Lars Fruergaard Jørgensen Steps Down Amidst Competitive Challenges

Novo Nordisk CEO Transition: Lars Fruergaard Jørgensen Steps Down Amidst Competitive Challenges

Novo Nordisk CEO Transition: Lars Fruergaard Jørgensen Steps Down Amidst Competitive Challenges
Trendline Trendline
Exobiosphere and Voyager Technologies Collaborate on ISS Biotech Mission

Exobiosphere and Voyager Technologies Collaborate on ISS Biotech Mission

Exobiosphere and Voyager Technologies Collaborate on ISS Biotech Mission
Trendline Trendline
Zura Bio Appoints Muzammil Mustufa as Chief Business Officer to Drive Strategic Growth

Zura Bio Appoints Muzammil Mustufa as Chief Business Officer to Drive Strategic Growth

Zura Bio Appoints Muzammil Mustufa as Chief Business Officer to Drive Strategic Growth
Trendline Trendline
Palatin Technologies Reports Q3 2026 Financial Results and Business Progress

Palatin Technologies Reports Q3 2026 Financial Results and Business Progress

Palatin Technologies Reports Q3 2026 Financial Results and Business Progress
Trendline Trendline
Lifecore Biomedical to Participate in CDMO Live Europe Conference

Lifecore Biomedical to Participate in CDMO Live Europe Conference

Lifecore Biomedical to Participate in CDMO Live Europe Conference
Trendline Trendline
Innate Pharma Reports Progress in Immunotherapy Pipeline and Financial Results for Q1 2026

Innate Pharma Reports Progress in Immunotherapy Pipeline and Financial Results for Q1 2026

Innate Pharma Reports Progress in Immunotherapy Pipeline and Financial Results for Q1 2026
Trendline Trendline
Immunome Submits NDA for Varegacestat and Reports Financial Results

Immunome Submits NDA for Varegacestat and Reports Financial Results

Immunome Submits NDA for Varegacestat and Reports Financial Results
Trendline Trendline
Perspective Therapeutics Advances VMT-α-NET with High Efficacy in Clinical Trials

Perspective Therapeutics Advances VMT-α-NET with High Efficacy in Clinical Trials

Perspective Therapeutics Advances VMT-α-NET with High Efficacy in Clinical Trials
Trendline Trendline
MacroGenics Sells Maryland Drug Manufacturing Plant to Bora for $122.5 Million

MacroGenics Sells Maryland Drug Manufacturing Plant to Bora for $122.5 Million

MacroGenics Sells Maryland Drug Manufacturing Plant to Bora for $122.5 Million
Trendline Trendline
Daiichi Sankyo Announces Ambitious Five-Year Plan for Oncology Leadership

Daiichi Sankyo Announces Ambitious Five-Year Plan for Oncology Leadership

Daiichi Sankyo Announces Ambitious Five-Year Plan for Oncology Leadership
Trendline Trendline
MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals for $122.5 Million

MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals for $122.5 Million

MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals for $122.5 Million
Trendline Trendline
Bora Group Acquires MacroGenics' Maryland Manufacturing Operations for $122.5 Million

Bora Group Acquires MacroGenics' Maryland Manufacturing Operations for $122.5 Million

Bora Group Acquires MacroGenics' Maryland Manufacturing Operations for $122.5 Million